CA3157849A1 - Methods of treating cancer with a sting agonist - Google Patents

Methods of treating cancer with a sting agonist

Info

Publication number
CA3157849A1
CA3157849A1 CA3157849A CA3157849A CA3157849A1 CA 3157849 A1 CA3157849 A1 CA 3157849A1 CA 3157849 A CA3157849 A CA 3157849A CA 3157849 A CA3157849 A CA 3157849A CA 3157849 A1 CA3157849 A1 CA 3157849A1
Authority
CA
Canada
Prior art keywords
compound
administered
dose
patient
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3157849A
Other languages
English (en)
French (fr)
Inventor
Zhijian Chen
Lijun Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Immunesensor Therapeutics Inc
Original Assignee
University of Texas System
Immunesensor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, Immunesensor Therapeutics Inc filed Critical University of Texas System
Publication of CA3157849A1 publication Critical patent/CA3157849A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3157849A 2019-10-14 2020-10-14 Methods of treating cancer with a sting agonist Pending CA3157849A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914881P 2019-10-14 2019-10-14
US62/914,881 2019-10-14
PCT/US2020/055633 WO2021076666A1 (en) 2019-10-14 2020-10-14 Methods of treating cancer with a sting agonist

Publications (1)

Publication Number Publication Date
CA3157849A1 true CA3157849A1 (en) 2021-04-22

Family

ID=73060121

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3157849A Pending CA3157849A1 (en) 2019-10-14 2020-10-14 Methods of treating cancer with a sting agonist

Country Status (7)

Country Link
US (1) US20230270773A1 (https=)
EP (1) EP4045059A1 (https=)
JP (1) JP2023500045A (https=)
CN (1) CN114929241A (https=)
AU (1) AU2020366354A1 (https=)
CA (1) CA3157849A1 (https=)
WO (1) WO2021076666A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022014110A (es) * 2020-05-15 2023-01-30 Immunesensor Therapeutics Inc Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ746112A (en) * 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
AU2017378782A1 (en) * 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
WO2018118665A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment

Also Published As

Publication number Publication date
WO2021076666A1 (en) 2021-04-22
EP4045059A1 (en) 2022-08-24
AU2020366354A1 (en) 2022-03-17
JP2023500045A (ja) 2023-01-04
CN114929241A (zh) 2022-08-19
US20230270773A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
AU2002356962B2 (en) Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
EP1465634A2 (en) Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
CN104684579A (zh) 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
US20210380695A1 (en) Sting agonist combination treatments with immune checkpoint inhibitors
CA3157849A1 (en) Methods of treating cancer with a sting agonist
US20230121320A1 (en) Sting agonist combination treatments with cytokines
WO2021076444A1 (en) Methods for treating breast cancer
HK40076423A (en) Methods of treating cancer with a sting agonist
KR20240046527A (ko) 암치료를 위한 신규 경구용 약학적 조성물
CN111727060B (zh) 治疗癌症的激动剂抗PD-1抗体与GnRH激动剂或GnRH拮抗剂的组合
US20200121720A1 (en) Nk-92 cells and il-15 agonist combination therapy
HK40087098A (zh) Sting激动剂与免疫检查点抑制剂的联合治疗
Eatmann et al. Potential use of thalidomide in glioblastoma treatment: an updated brief overview. Metabolites. 2023; 13: 543
US20220251203A1 (en) Use of anti-pd-1 antibody in combination with famitinib in preparation of drug for treating tumors
Mohamed et al. Potential use of thalidomide in glioblastoma treatment: an updated brief overview
Yang et al. EXTH-77. POLIO VIROTHERAPY OF MURINE BRAIN TUMORS INDUCES MICROGLIA PROLIFERATION AND INFLAMMATION THAT IS POTENTIATED BY IMMUNE CHECKPOINT BLOCKADE
WO2025021587A1 (en) Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof
WO2021224381A1 (en) Combination therapy for treating cancer
CN118718000A (zh) 药物组合物及其在制备治疗肾癌的药物中的用途
HK40021263A (en) Nk-92 cells and il-15 agonist combination therapy

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241004

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241004

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241004

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241009

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241009

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241118

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241211

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241211

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250422

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251125